The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
Coronavirus disease 2019 (COVID-19) is a recently emerging disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Notably, the safety of immunosuppressive medications is a major concern during an infectious disease pandemic. Rituximab (RTX), as a monoclonal antibody against...
Guardado en:
Autores principales: | Pourya Yarahmadi, Mohammad Alirezaei, Seyed Mohammad Forouzannia, Abdorreza Naser Moghadasi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Shiraz University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/280ff03242c646f0ab5d6c85e329a954 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
por: Branka Marinović, et al.
Publicado: (2021) -
PTI y embarazo: Una experiencia con Rituximab
por: Campoverde V,Priscila, et al.
Publicado: (2017) -
Methodology for assessing herd immunity to the SARS-CoV-2 virus in the context of the COVID-19 pandemic
por: A. Yu. Popova, et al.
Publicado: (2021) -
Studying Humoral Immune Response at Mild and Asymptomatic COVID-19 Forms
por: S. V. Balakhonov, et al.
Publicado: (2020) -
Population immunity to SARS-CoV-2 virus in residents of the Irkutsk Region in the dynamics of the epidemic
por: S. V. Balakhonov, et al.
Publicado: (2021)